Literature DB >> 29876318

Proton beam therapy for malignant pleural mesothelioma.

Shahed N Badiyan1, Jason K Molitoris1, Mingyao Zhu1, Erica Glass1, Tejan Diwanji1, Charles B Simone1.   

Abstract

Malignant pleural mesothelioma (MPM) is a rare disease with a poor prognosis. Surgical techniques have made incremental improvements over the last few decades while new systemic therapies, including immunotherapies, show promise as potentially effective novel therapies. Radiation therapy has historically been used only in the palliative setting or as adjuvant therapy after extrapleural pneumonectomy, but recent advances in treatment planning and delivery techniques utilizing intensity-modulated radiation therapy and more recently pencil-beam scanning (PBS) proton therapy, have enabled the delivery of radiation therapy as neoadjuvant or adjuvant therapy after an extended pleurectomy and decortication or as definitive therapy for patients with recurrent or unresectable disease. In particular, PBS proton therapy has the potential to deliver high doses of irradiation to the entire effected pleura while significantly reducing doses to nearby organs at risk. This article describes the evolution of radiation therapy for MPM and details how whole-pleural PBS proton therapy is delivered to patients at the Maryland Proton Treatment Center.

Entities:  

Keywords:  Malignant pleural mesothelioma (MPM); pencil-beam scanning (PBS); proton beam therapy; radiation; spot scanning

Year:  2018        PMID: 29876318      PMCID: PMC5960661          DOI: 10.21037/tlcr.2018.04.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  70 in total

Review 1.  Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D).

Authors:  Hasan Fevzi Batirel
Journal:  Ann Transl Med       Date:  2017-06

2.  Helical tomotherapy for resected malignant pleural mesothelioma: dosimetric evaluation and toxicity.

Authors:  Philippe Giraud; Alma Sylvestre; Sofia Zefkili; Albert Lisbona; Pierre Bonnette; Françoise Le Pimpec Barthes; Edouard Paris; Christian Perigaud; Alexia Savignoni; Marc-André Mahé
Journal:  Radiother Oncol       Date:  2011-08-22       Impact factor: 6.280

3.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

Review 4.  Malignant pleural mesothelioma: the standard of care and challenges for future management.

Authors:  Jan P van Meerbeeck; Arnaud Scherpereel; Veerle F Surmont; Paul Baas
Journal:  Crit Rev Oncol Hematol       Date:  2010-05-13       Impact factor: 6.312

5.  Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Marc de Perrot; Ronald Feld; Natasha B Leighl; Andrew Hope; Thomas K Waddell; Shaf Keshavjee; B C John Cho
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-19       Impact factor: 5.209

6.  Radiation therapy in the management of patients with mesothelioma.

Authors:  W Gordon; K H Antman; J S Greenberger; R R Weichselbaum; J T Chaffey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-01       Impact factor: 7.038

7.  Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Claus Andrup Kristensen; Trine Juhler Nøttrup; Anne Kiil Berthelsen; Flemming Kjaer-Kristoffersen; Jesper Ravn; Jens Benn Sørensen; Svend-Aage Engelholm
Journal:  Radiother Oncol       Date:  2009-04-11       Impact factor: 6.280

8.  A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.

Authors:  Noelle O'Rourke; Jose Curto Garcia; Jim Paul; Claire Lawless; Rhona McMenemin; Jennifer Hill
Journal:  Radiother Oncol       Date:  2007-06-22       Impact factor: 6.280

9.  Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.

Authors:  C Boutin; F Rey; J R Viallat
Journal:  Chest       Date:  1995-09       Impact factor: 9.410

10.  Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.

Authors:  Lucian R Chirieac; Justine A Barletta; Beow Y Yeap; William G Richards; Tamara Tilleman; Raphael Bueno; Elizabeth H Baldini; John Godleski; David J Sugarbaker
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

View more
  4 in total

1.  Advances in radiation therapy for thoracic malignancies.

Authors:  Charles B Simone; Shahed N Badiyan; Pranshu Mohindra
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 2.  Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma.

Authors:  Gwendolyn Cramer; Charles B Simone; Theresa M Busch; Keith A Cengel
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.

Authors:  Stephanie R Rice; Yun R Li; Theresa M Busch; Michele M Kim; Sally McNulty; Andrea Dimofte; Timothy C Zhu; Keith A Cengel; Charles B Simone
Journal:  Photochem Photobiol       Date:  2018-12-28       Impact factor: 3.421

Review 4.  Controversies in the role of radiotherapy in pleural mesothelioma.

Authors:  Gerard G Hanna; Thomas John; David L Ball
Journal:  Transl Lung Cancer Res       Date:  2021-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.